Navigation Links
Tosedostat OPAL Study Final Results Selected for Oral Presentation at the 2011 American Society of Hematology (ASH) Annual Meeting
Date:12/6/2011

e "EMA"), the potential failure of tosedostat to prove safe and effective for the treatment of AML, myelodysplastic syndromes, multiple myeloma, blood related cancers and solid tumors as determined by the FDA and/or the EMA, that the FDA may not accept the proposed clinical trial of tosedostat and/or may request additional trials, that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials,  determinations by regulatory, patent, and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing, and selling pixantrone and tosedostat, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

 

 

Media Contact:

Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com
www.CellTherapeutics.com/press_room

Investors Contact:

Ed Bell
T: 206.282.7100
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
www.CellTherapeutics.com/investors

Medical Information Contact:

T: 800.715.0944
E: info@askarm.com

 


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmathene Announces Publication of Phase I Study Results for Anthrax Anti-toxin Valortim®
2. Aethlon Medical Announces Approval and Initiation of Cancer Research Study to Target Tumor-Secreted Exosomes
3. New Study Shows AFECTAIR® Significantly Improved Delivery of Nitric Oxide Under Simulated Neonatal Ventilatory Conditions
4. First Patient Enrolled in Therakos Phase Two Study for Treatment of Graft-versus-Host Disease
5. New Gene Study of ADHD Points to Defects in Brain Signaling Pathways
6. RECITAL Study Presents Excellent Outcomes and Rapid Patient Recovery With Revolutionary Femoral Access Procedure
7. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome
8. Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinsons Disease
9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
10. BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA
11. New Study Points to Novel Mechanism by Which Tumors Escape Recognition by the Immune System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015  New product launches are ... leading role in educating thought leaders about new products, ... heavily influence how well a new therapy performs at ... from research and consulting leader Best Practices, LLC, critical ... to focus on are early stage thought leader (TL) ...
(Date:7/2/2015)... 2, 2015 According to a new ... Brain Stimulation, Spinal Cord Stimulation, Transcranial Magnetic Stimulation), Application (Depression, ... to 2020", published by MarketsandMarkets, the global Neuromodulation Market is ... reach $6.20 Billion by 2020, at a CAGR of 11.2% ... 8 4 market data T ables ...
(Date:7/2/2015)... , July 2, 2015 Numotion,s Board of ... announced that Tamas Feitel has joined the ... Numotion after a highly successful 18 year career at ... driving strategy, profitability, and productivity to result in significant ... position was Chief Financial Officer for GE Healthcare Global ...
Breaking Medicine Technology:Medical Affairs Role in Thought Leader Education is Key Success Factor for New Product Launches in the Pharmaceutical Industry 2Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4Numotion Names Tamas Feitel Chief Financial Officer 2
... HAYWARD, Calif., May 3, 2012  Anthera Pharmaceuticals, Inc. (NASDAQ: ... for the quarter ended March 31, 2012. ... first quarter ended March 31, 2012 were $20.1 million, as ... 31, 2011. The decrease in operating expenses can be primarily ...
... Calif., May 3, 2012  IRIDEX Corporation (Nasdaq: ... quarter ended March 31, 2012. Due to the sale ... the Company,s financial statements reflect the results of its ... commentary relates to the results of its continuing ophthalmology ...
Cached Medicine Technology:Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update 2Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update 3Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update 4IRIDEX Reports 2012 First Quarter Results 2IRIDEX Reports 2012 First Quarter Results 3IRIDEX Reports 2012 First Quarter Results 4IRIDEX Reports 2012 First Quarter Results 5IRIDEX Reports 2012 First Quarter Results 6
(Date:7/4/2015)... IRVINE, California (PRWEB) , ... July 04, 2015 ... ... has earned the solar industry’s leading recognition of technical sales expertise from the ... Certified PV Technical Sales ProfessionalTM. NABCEP is the most highly respected and well ...
(Date:7/3/2015)... ... July 03, 2015 , ... Scientists at several top US cancer centers ... minimal asbestos exposure. Click here to read the complete story , just posted ... Center, Cedars Sinai Medical Center, and New York University exposed mice with a mutation ...
(Date:7/3/2015)... CT (PRWEB) , ... July 03, 2015 , ... Smoothies ... home is a good blender and easily accessible, quality ingredients. Aurora Natural is proud ... smoothie for an added boost of fiber, protein, antioxidants, vitamins and minerals! , Aurora ...
(Date:7/3/2015)... ... July 03, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The ... he says will reveal biblical truth and expose popular lies regarding proper relationships according ... Don’t Have Sex”, immediately goes into the core of the subject by explaining why ...
(Date:7/2/2015)... ... 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce the opening of ... located in the Lone Star State. The premium frozen yogurt chain was listed as ... store, which opened July 1 at Duke’s Travel Plaza, is located at:, 30176 Hwy ...
Breaking Medicine News(10 mins):Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:sweetFrog Expands Texas Footprint with Location in Canton 2
... 'wonder drug' after it was found to halve the risk of ... that the drug can also serve as a potential cure //for ... ,In this particular study, which tracked 5,000 patients in 39 countries, ... as compared to 127 cases in patients who were on Herceptin ...
... with the promotion and co-coordination of research in various ... the country and encourage young minds to work, //it ... to Scientists. ,This was stated by health minister ... K Kasturirangan, who headed the performance appraisal board constituted ...
... Kyoto University have found that daily gargling with povidione-iodine reduced ... study have been published in the American Journal of Preventive ... volunteers between the age group of 18 to 65. , ... first group gargled water with povidone-iodine, the second group gargled ...
... for small renal cell carcinoma (RCC) tumors; however, it ... preoperatively. // ,Although no specific tumor markers have ... a variable predictor of lymph node and distant metastasis ... to determine the nuclear grade of RCC without removing ...
... Demicheli an Italian epidemiologist as done a systematic review of ... (MMR) vaccine.// The study is focused to find out the ... it is believed that use of MMR vaccine shots in ... millions of children around the world and concluded that MMR ...
... A 60 mg low-dose version of the prescription weight-loss ... was found to be safe, effective and tolerable in ... the 2005 Annual Meeting of NAASO, The Obesity Society ... compared orlistat 60 mg plus diet to placebo plus ...
Cached Medicine News:Health News:Daily Gargling May Prevent Common Colds 2Health News:A Novel Method Of Detection Of High Nuclear Grade Localized Renal Cell Carcinoma 2Health News:MMR Vaccination not linked to Autism 2Health News:Weight-Loss Medication Evaluated By Nutrition Expert 2
... early 1990s, the "Reversed" shoulder prosthesis has ... great success. More recently, an ever-growing number ... begun to champion this prosthesis and the ... This reversed technology is the result of ...
... FLUORAT®-02-PANORAMA spectrofluorometer is ... instrument among the ... is intended for ... analysis, and for ...
... The Gemini XPS spectrofluorometer ... measurements as required by ... assays. Cellular and molecular ... drug screening, and SNP ...
The FluoroMax-3 is the entry level spectrofluorometer from Spex®, yet offers features not found in most of the top models of the competition....
Medicine Products: